High levels of nuclear RAD21 staining correlate with poor disease-specific survival of colorectal cancer patients with KRAS mutations (Deb et al., 2014) and with early relapse in patients with high-grade luminal, basal, or HER2 breast cancers (Xu et al., 2011). This evidence concerns the gene KRAS and breast carcinoma.